| Loretta Hilgenkamp, | |
|
20703 County Road 24, Arlington, NE 68002-5124 | |
| (303) 501-4401 | |
| Not Available |
| Full Name | Loretta Hilgenkamp |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 20703 County Road 24, Arlington, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154712628 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RO97332 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Loretta Hilgenkamp, 20703 County Road 24, Arlington, NE 68002-5124 Ph: () - | Loretta Hilgenkamp, 20703 County Road 24, Arlington, NE 68002-5124 Ph: (303) 501-4401 |
News Archive
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
An experimental drug designed to treat cancers with a particular genetic fault has shown promising results in a small clinical trial.
Surgical teams now can get faster and more complete information on the status of their patients' coagulation state from the ROTEM hemostasis analyzer, recently cleared by the Food and Drug Administration.
Heart scans for patients with chest pains could save thousands of lives in the UK, research suggests.The life-saving scans helped to spot those with heart disease so they could be given treatments to prevent heart attacks.
Ultraviolet lights could reduce the spread of tuberculosis in hospital wards and waiting rooms by 70%, according to a new study, published in PLoS Medicine today.
› Verified 5 days ago
Shirley Ann Holck, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 705 N 9th St, Arlington, NE 68002 Phone: 402-478-4121 |